Subretinal Macugen® for Neovascular Age-Related Macular Degeneration

Inclusion Criteria: * Adults aged 50 years and older with neovascular AMD proven by FA * Patients who at baseline * Have a BCVA letter score in the study eye between 20/40 to 20/320 using an ETDRS chart measured at 4 meters or Snellen equivalent * Have a CNV lesion of any type in the study eye with the following characteristics as determined by fluorescein angiography: * Evidence that CNV extends under the geometric center of the foveal avascular zone. * Previous state-of-the-art therapy for the disease is deemed ineffective with following characteristics are given: * Loss of visual acuity (2 or more Snellen lines) in the previous 3 months defined as either OR * ≥10% increase in the lesion diameter as assessed by fluorescein angiography in the previous 3 months * Ability of subject to understand character and individual consequences of clinical trial. * Signed and dated informed consent of the subject must be available before start of any specific trial procedures. * Women with childbearing potential practicing a medically accepted contraception (negative pregnancy test result, serum or urine at trial entry). Exclusion Criteria: * Subjects presenting with any of the following criteria will not be included in the trial: * Have a relevant ocular disease which may be associated with increased intraocular VEGF levels (namely uveitis, neovascular glaucoma, diabetic retinopathy, diabetic maculopathy, ocular ischemic syndrome, retinal vessel occlusion) * Had previous vitrectomy surgery for whatsoever reason * Are not pseudophakic * Have a \>50% area of scarring of the whole CNV lesion size as seen in FA * Arterial hypertension refractory to medical treatment * Pregnancy and lactation. * History of hypersensitivity to the investigational medicinal product or to any drug with similar chemical structure or to any excipient present in the pharmaceutical form of the investigational medicinal product. * Participation in other clinical trials during the present clinical trial or within the last 3 months. * Medical or psychological condition that would not permit completion of the trial or signing of informed consent. * Suspected or present ocular or periocular infection